Gilead Sciences Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now owns 132,964 shares in the company, valued at $10,881,773.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Gilead Sciences Inc. (NASDAQ:GILD) opened at 78.97 on Thursday. Gilead Sciences Inc. has a 12-month low of $76.67 and a 12-month high of $111.11. The stock has a market capitalization of $104.21 billion, a P/E ratio of 6.93 and a beta of 1.06. The firm’s 50-day moving average is $79.44 and its 200 day moving average is $85.67.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the previous year, the firm earned $3.15 earnings per share. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.38%. Gilead Sciences’s payout ratio is 16.56%.
A number of hedge funds have recently added to or reduced their stakes in GILD. Van Hulzen Asset Management LLC raised its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the last quarter. Joel Isaacson & Co. LLC raised its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the last quarter. Roble Belko & Company Inc raised its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC raised its stake in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the last quarter. Hedge funds and other institutional investors own 77.94% of the company’s stock.
Several equities analysts have weighed in on GILD shares. Gabelli started coverage on shares of Gilead Sciences in a report on Wednesday, June 1st. They issued a “buy” rating and a $109.00 target price on the stock. Robert W. Baird restated an “outperform” rating and issued a $135.00 price objective on shares of Gilead Sciences in a report on Monday, June 6th. Morgan Stanley restated a “hold” rating on shares of Gilead Sciences in a report on Monday, June 6th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, June 8th. Finally, Leerink Swann restated a “buy” rating and issued a $120.00 price objective (down from $123.00) on shares of Gilead Sciences in a report on Thursday, June 9th. Eleven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $104.34.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.